These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 18228213)
1. Radioimmunotherapy in follicular lymphomas, a retrospective analysis of the Polish Lymphoma Research Group's (PLRG) experience. Jurczak W; Hubalewska-Dydejczyk A; Giza A; Sowa-Staszczak A; Wróbel T; Mazur G; Boguradzki P; Knopińska-Posłuszny W; Huszno B; Skotnicki AB Nucl Med Rev Cent East Eur; 2007; 10(2):91-7. PubMed ID: 18228213 [TBL] [Abstract][Full Text] [Related]
2. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). Zinzani PL; Tani M; Pulsoni A; Gobbi M; Perotti A; De Luca S; Fabbri A; Zaccaria A; Voso MT; Fattori P; Guardigni L; Ronconi S; Cabras MG; Rigacci L; De Renzo A; Marchi E; Stefoni V; Fina M; Pellegrini C; Musuraca G; Derenzini E; Pileri S; Fanti S; Piccaluga PP; Baccarani M Lancet Oncol; 2008 Apr; 9(4):352-8. PubMed ID: 18342572 [TBL] [Abstract][Full Text] [Related]
3. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. Morschhauser F; Radford J; Van Hoof A; Vitolo U; Soubeyran P; Tilly H; Huijgens PC; Kolstad A; d'Amore F; Gonzalez Diaz M; Petrini M; Sebban C; Zinzani PL; van Oers MH; van Putten W; Bischof-Delaloye A; Rohatiner A; Salles G; Kuhlmann J; Hagenbeek A J Clin Oncol; 2008 Nov; 26(32):5156-64. PubMed ID: 18854568 [TBL] [Abstract][Full Text] [Related]
4. Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia. Schilder R; Molina A; Bartlett N; Witzig T; Gordon L; Murray J; Spies S; Wang H; Wiseman G; White C Cancer Biother Radiopharm; 2004 Aug; 19(4):478-81. PubMed ID: 15453962 [TBL] [Abstract][Full Text] [Related]
5. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122 [TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study. Ibatici A; Pica GM; Nati S; Vitolo U; Botto B; Ciochetto C; Petrini M; Galimberti S; Ciabatti E; Orciuolo E; Zinzani PL; Cascavilla N; Guolo F; Fraternali Orcioni G; Carella AM Br J Haematol; 2014 Mar; 164(5):710-6. PubMed ID: 24344981 [TBL] [Abstract][Full Text] [Related]
7. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma. Witzig TE; White CA; Gordon LI; Wiseman GA; Emmanouilides C; Murray JL; Lister J; Multani PS J Clin Oncol; 2003 Apr; 21(7):1263-70. PubMed ID: 12663713 [TBL] [Abstract][Full Text] [Related]
8. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. Witzig TE; Flinn IW; Gordon LI; Emmanouilides C; Czuczman MS; Saleh MN; Cripe L; Wiseman G; Olejnik T; Multani PS; White CA J Clin Oncol; 2002 Aug; 20(15):3262-9. PubMed ID: 12149300 [TBL] [Abstract][Full Text] [Related]
9. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016 [TBL] [Abstract][Full Text] [Related]
10. Radioimmunotherapy using 131I-rituximab in patients with advanced stage B-cell non-Hodgkin's lymphoma: initial experience. Bienert M; Reisinger I; Srock S; Humplik BI; Reim C; Kroessin T; Avril N; Pezzutto A; Munz DL Eur J Nucl Med Mol Imaging; 2005 Oct; 32(10):1225-33. PubMed ID: 15937686 [TBL] [Abstract][Full Text] [Related]
11. Dosimetry of 90Y-ibritumomab tiuxetan as consolidation of first remission in advanced-stage follicular lymphoma: results from the international phase 3 first-line indolent trial. Delaloye AB; Antonescu C; Louton T; Kuhlmann J; Hagenbeek A J Nucl Med; 2009 Nov; 50(11):1837-43. PubMed ID: 19837764 [TBL] [Abstract][Full Text] [Related]
12. Relapsed follicular lymphoma sequentially treated with rituximab and 90Y-ibritumomab tiuxetan. Case report. Papajik T; Prochazka V; Raida L; Kubova Z; Myslivecek M; Drymlova J; Buriankova E; Kucerova L; Indrak K Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2007 Jun; 151(1):109-12. PubMed ID: 17690751 [TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy of (90)Y ibritumomab tiuxetan therapy in follicular non-Hodgkin lymphoma and health-related quality of life. Andrade-Campos MM; Montes-Limón AE; Soro-Alcubierre G; Grasa JM; Lopez-Gómez L; Baringo T; Giraldo P Ann Hematol; 2014 Dec; 93(12):1985-92. PubMed ID: 24985089 [TBL] [Abstract][Full Text] [Related]
14. 131I-Anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkins lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital. Turner JH; Martindale AA; Boucek J; Claringbold PG; Leahy MF Cancer Biother Radiopharm; 2003 Aug; 18(4):513-24. PubMed ID: 14503945 [TBL] [Abstract][Full Text] [Related]
15. [90Y-ibritumomab tiuxetan in patients with follicular lymphoma relapsing or refractory to rituximab]. Aurer I; Huić D; Zuvić M; Sever-Prebilić M; Ajduković R; Radman I; Skare-Librenjak L; Ostojić-Kolonić S; Labar B Lijec Vjesn; 2006; 128(7-8):224-7. PubMed ID: 17087138 [TBL] [Abstract][Full Text] [Related]